Toxic Shock Syndrome – Evolution of an Emerging Disease

Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 697)

Abstract

Toxic shock syndrome (TSS) was originally described in 1978 in seven patients: four females and three males who presented acutely with fever, hypotension, mucous membrane hyperemia, a scarlatiniform rash (that ultimately desquamated), and multiple organ system failure [1]. A unique Staphylococcus aureus strain, which produced a new epidermal toxin, was isolated from five of the children. By January 1980, 35 cases had been observed, of which 25 were in females with an average age of 28.2 years; only 10 were in males with an average age of 11.6 years [2]. Seven of 10 males had an identifiable focus of S. aureus infection, whereas 20 of 22 females had a watery vaginal discharge from which S. aureus was isolated. Shortly thereafter, cases of TSS were further associated with menstruation and the use of tampons.

Keywords

Dioxide Corticosteroid Staphylococcus Clindamycin Fasciitis 

References

  1. 1.
    Todd J, Fishaut M, Kapral F, Welch T. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;2(8100):1116–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Todd JK, Todd BH, Franco-Buff A, Smith CM, Lawellin DW. Influence of focal growth conditions on the pathogenesis of toxic shock syndrome. J Infect Dis. 1987;155(4):673–81.PubMedGoogle Scholar
  3. 3.
    Shands KN, Schmid GP, Dan BB, Blum D, Guidotti RJ, Hargrett NT, et al. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303(25):1436–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Todd JK, Wiesenthal AM, Ressman M, Caston SA, Hopkins RS. Toxic shock syndrome. II. Estimated occurrence in Colorado as influenced by case ascertainment methods. Am J Epidemiol. 1985;122(5):857–67.PubMedGoogle Scholar
  5. 5.
    Todd J, Kurtz B, Combs P, Todd A, Anderson J Epidemiology of toxic shock syndrome 1970–1996. Royal Society of Medicine Congress Symposium Series; 1998. p. 229.Google Scholar
  6. 6.
    Petitti DB, Reingold A, Chin J. The incidence of toxic shock syndrome in Northern California: 1972 through 1983. JAMA. 1986;255(3):368–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Reingold AL. Epidemiology of toxic-shock syndrome, United States, 1960–1984. MMWR CDC Surveill Summ. 1984;33(3):19SS–22SS.PubMedGoogle Scholar
  8. 8.
    Broome CV. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis. 1989;11(Suppl 1):S14–21.PubMedGoogle Scholar
  9. 9.
    Tofte RW, Williams DN. Toxic shock syndrome. Evidence of a broad clinical spectrum. JAMA. 1981;246(19):2163–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Wiesenthal AM, Todd JK. Toxic shock syndrome in children aged 10 years or less. Pediatrics. 1984;74(1):112–7.PubMedGoogle Scholar
  11. 11.
    Reeves MW, Pine L, Feeley JC, Wells DE. Presence of toxic shock toxin in toxic shock and other clinical strains of Staphylococcus aureus. Infect Immun. 1984;46(2):590–7.PubMedGoogle Scholar
  12. 12.
    Bohach GA, Kreiswirth BN, Novick RP, Schlievert PM. Analysis of toxic shock syndrome isolates producing staphylococcal enterotoxins B and C1 with use of southern hybridization and immunologic assays. Rev Infect Dis. 1989;11(Suppl 1):S75–81. Discussion S–2.PubMedGoogle Scholar
  13. 13.
    Choi Y, Lafferty JA, Clements JR, Todd JK, Gelfand EW, Kappler J, et al. Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med. 1990;172(3):981–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Vergeront JM, Stolz SJ, Crass BA, Nelson DB, Davis JP, Bergdoll MS. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: implications for toxic-shock syndrome. J Infect Dis. 1983;148(4):692–8.PubMedGoogle Scholar
  15. 15.
    Kansal R, Davis C, Hansmann M, Seymour J, Parsonnet J, Modern P, et al. Structural and functional properties of antibodies to the superantigen TSST-1 and their relationship to menstrual toxic shock syndrome. J Clin Immunol. 2007;27(3):327–38.CrossRefPubMedGoogle Scholar
  16. 16.
    Luca-Harari B, Ekelund K, van der Linden M, Staum-Kaltoft M, Hammerum AM, Jasir A. Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004. J Clin Microbiol. 2008;46(1):79–86.CrossRefPubMedGoogle Scholar
  17. 17.
    Lina G, Gillet Y, Vandenesch F, Jones ME, Floret D, Etienne J. Toxin involvement in staphylococcal scalded skin syndrome. Clin Infect Dis. 1997;25(6):1369–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Chan KH, Kraai TL, Richter GT, Wetherall S, Todd JK. Toxic shock syndrome and rhinosinusitis in children. Arch Otolaryngol Head Neck Surg. 2009;135(6):538–42.CrossRefPubMedGoogle Scholar
  19. 19.
    Ferguson MA, Todd JK. Toxic shock syndrome associated with Staphylococcus aureus sinusitis in children. J Infect Dis. 1990;161(5):953–5.PubMedGoogle Scholar
  20. 20.
    Takahashi N, Uehara R, Nishida H, Sakuma I, Yamasaki C, Takahashi K, et al. Clinical features of neonatal toxic shock syndrome-like exanthematous disease emerging in Japan. J Infect. 2009;59(3):194–200.CrossRefPubMedGoogle Scholar
  21. 21.
    Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med. 1980;303(25):1429–35.CrossRefPubMedGoogle Scholar
  22. 22.
    Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis. J Infect Dis. 1988;158(1):23–8.PubMedGoogle Scholar
  23. 23.
    Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18(12):1096–100.CrossRefPubMedGoogle Scholar
  24. 24.
    Todd JK, Ressman M, Caston SA, Todd BH, Wiesenthal AM. Corticosteroid therapy for patients with toxic shock syndrome. JAMA. 1984;252(24):3399–402.CrossRefPubMedGoogle Scholar
  25. 25.
    Todd JK. Therapy of toxic shock syndrome. Drugs. 1990;39(6):856–61.CrossRefPubMedGoogle Scholar
  26. 26.
    Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003;35(9):683–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Descloux E, Perpoint T, Ferry T, Lina G, Bes M, Vandenesch F, et al. One in five mortality in non-menstrual toxic shock syndrome versus no mortality in menstrual cases in a balanced French series of 55 cases. Eur J Clin Microbiol Infect Dis. 2008;27(1):37–43.CrossRefPubMedGoogle Scholar
  28. 28.
    American Academy of Pediatrics. Committee on infectious diseases. Severe invasive group A streptococcal infections: a subject review. Pediatrics. 1998;101(1 Pt 1):136–40.Google Scholar
  29. 29.
    Helgerson SD, Mallery BL, Foster LR. Toxic shock syndrome in Oregon. Risk of recurrence. JAMA. 1984;252(24):3402–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of EpidemiologyThe Children’s HospitalAuroraUSA

Personalised recommendations